Company Overview
About Ansa Biotechnologies
Ansa Biotechnologies is a synthetic DNA synthesis company developing enzymatic DNA writing technology to overcome the length and quality limitations of chemical DNA synthesis. Founded in 2021 and headquartered in Emeryville, California, Ansa uses engineered terminal deoxynucleotidyl transferase (TdT) enzymes rather than phosphoramidite chemistry to build DNA strands, enabling synthesis of longer sequences with higher fidelity and fewer toxic reagents. The company emerged from research at UC Berkeley and Lawrence Berkeley National Laboratory.
Business Model & Competitive Advantage
The company raised $68 million in Series B funding in 2023, backed by investors including Data Collective (DCVC), The Engine, and Andreessen Horowitz Bio, to commercialize its enzymatic synthesis platform. Ansa's technology is particularly relevant for applications requiring long DNA fragments — synthetic biology gene construction, therapeutic oligonucleotides, and data storage — where conventional synthesis reaches length and error-rate ceilings. By 2024-2025, the company has been delivering custom DNA synthesis orders to pharmaceutical, agricultural biotech, and research customers.
Competitive Landscape 2025–2026
In 2025, Ansa Biotechnologies operates at a critical juncture in synthetic biology infrastructure, as the field requires DNA synthesis capabilities far exceeding what chemical methods can reliably deliver. The company competes with Twist Bioscience, Integrated DNA Technologies (IDT), and emerging enzymatic competitors like DNA Script. Ansa's 2025-2026 priorities include scaling throughput, pursuing FDA engagement for therapeutic oligonucleotide applications, and expanding into DNA data storage partnerships where unprecedented sequence lengths are commercially valuable.
Open Positions
Reddit Discussions
Key Differentiators
Strong Challenger
Ansa Biotechnologies is an established challenger with significant market presence and competitive offerings in Healthcare.
Frequently Asked Questions
Not So Random Others
Zeffy
Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs
Oda Studio
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Cursor
Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities dir
Kindful
Kindful is a donor management and fundraising platform designed for nonprofit organizations to manage relationships, track donations, and execute fundraising campaigns. The company serves small to mid
Compare Ansa Biotechnologies with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Ansa Biotechnologies? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Ansa Biotechnologies Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Ansa Biotechnologies vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →